Harrow (NASDAQ:HROW – Get Free Report) and MediciNova (NASDAQ:MNOV – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.
Volatility & Risk
Harrow has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
Valuation & Earnings
This table compares Harrow and MediciNova”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harrow | $272.30 million | 4.55 | -$5.14 million | ($1.00) | -33.08 |
| MediciNova | $410,000.00 | 398.56 | -$12.00 million | ($0.21) | -15.81 |
Harrow has higher revenue and earnings than MediciNova. Harrow is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
72.8% of Harrow shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Harrow and MediciNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harrow | -13.51% | -38.00% | -3.37% |
| MediciNova | -1,168.70% | -26.51% | -24.39% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Harrow and MediciNova, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harrow | 1 | 2 | 9 | 0 | 2.67 |
| MediciNova | 1 | 1 | 3 | 2 | 2.86 |
Harrow currently has a consensus price target of $66.38, indicating a potential upside of 100.65%. MediciNova has a consensus price target of $7.75, indicating a potential upside of 133.43%. Given MediciNova’s stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Harrow.
Summary
MediciNova beats Harrow on 9 of the 15 factors compared between the two stocks.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
